Delays to GenSight Biologics’ eye disease gene therapy are leading toward a cash crunch. With the cash runway due to end early next year and Lumevoq still being reviewed in Europe, GenSight is looking ...
GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal ...
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a ...
A phase 3 trial of GenSight Biologics’ Leber hereditary optic neuropathy (LHON) gene therapy has missed its primary endpoint. The AAV gene therapy was no better than placebo at improving vision at 48 ...
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene ...
Operating income decreased to €0.04 million from €1.7 million over the period. In the first half of 2025, income mainly reflects the Research Tax Credit (CIR), partly offset by the accounting impact ...
As of 21 March at 4:00:00 pm GMT-4. Market open. PARIS, March 19, 2025--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on ...
On the basis of the share capital of the Company immediately before completion of the Fundraising, the interest of a shareholder who held 1.00% of the Company's share capital at that time and who did ...
Final certification by the auditors will take place after completion of the required procedures to file the universal registration document with the Autorité des Marchés Financiers (AMF) 1. Going ...
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene ...
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal ...
A French biotech company is hoping that longer-term follow-up data will vindicate its gene therapy for a disease that causes vision loss following its second failed Phase III study. Paris-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results